Zoetis: The animal top dog with new therapies
Scores at time of recommendation (November 1, 2025)
5-year stock timeline
2026 Q1–Q2 (May–Aug)
Zoetis reported first-quarter 2026 results and continued regular dividend payments with a quarterly dividend of $0.53 declared on ex-date April 20, 2026. [5][3]
Investors positioned the company as a steady large-cap animal-health compounder with predictable cash flow and a shareholder-return focus centered on dividend growth and buybacks. Near-term attention remained on execution within companion-animal and production-animal segments and margin management. [5][3]
The stock showed recovery and rally tendencies following earlier 2024–2025 consolidation, with dividend yield and steady guidance supporting accumulation. [5]
2025 (full year)
Zoetis continued sequential dividend increases and regular quarterly payouts, with 2025 quarterly dividends of $0.50 and an annualized dividend increase versus 2024. Company execution remained centered on organic growth plus tuck-in acquisitions. [3][12]
The market viewed Zoetis as a resilient growth-with-income name. Strong brand positioning in companion animal products and ongoing investment in R&D and small acquisitions kept the growth narrative intact despite macro volatility, though sentiment remained constructive but valuation-conscious. [12]
The stock traded through ranges with episodic rallies around earnings and dividend or guidance beats. [3]
2024 (calendar year)
Zoetis raised the quarterly dividend to $0.432 and reported steady revenue growth across segments while executing bolt-on acquisitions and advancing pipeline progress in diagnostics and biologics. [3][10]
Investors continued to treat the company as a defensive growth compounder in animal health. Incremental M&A and diagnostic and biologic investments reinforced the long-term growth story and supported multiple expansion at times. [10]
The stock generally trended higher through 2024 with corrections on market-wide risk-off days and profit-taking after run-ups. [3]
2023 (calendar year)
Zoetis increased its quarterly dividend to approximately $0.375 and delivered solid results while continuing to prioritize organic growth, R&D, and targeted acquisitions. [3][14]
Market perception centered on Zoetis as a durable compounder benefiting from secular growth in pet care and livestock biotechnology, viewed as less cyclical than many peers and attracting patient growth-income investors. [14]
The stock staged a multi-quarter recovery from 2022 weakness and entered a more sustained uptrend as results and guidance stabilized. [3]
2022 (calendar year)
Zoetis raised dividends to approximately $0.325 quarterly and navigated a volatile macro environment. A 4-for-1 stock split was recorded on November 21, 2022. [13][3]
Following 2021–2022 post-COVID normalization, investors reassessed growth expectations. The split and continued dividend growth signaled management confidence and shareholder-friendly policy. Some investors re-priced near-term growth lower while others focused on long-term compounding. [13][3]
The stock experienced a material drawdown during 2022 market volatility, then formed a base and range late in the year ahead of the split and subsequent recovery. [13]
2021 (calendar year)
Zoetis reinstated and grew its quarterly dividend to $0.25 (annualized approximately $1.00 in 2021) and continued integration of recent acquisitions. Company performance benefited from post-pandemic demand normalization in animal health. [14][11]
The investor view shifted from pandemic-era volatility toward a normalized, predictable growth profile. Zoetis was increasingly framed as a high-quality, cash-generative specialty healthcare compounder with steady margin prospects. [11]
The stock moved higher as pandemic impacts eased, followed by rotational consolidation as markets rebalanced sector exposure. [14]
Key Points
- World market leader for animal health with an untouchable moat thanks to patents and sales structures built up over decades
- Crisis-proof customer base - animal health is never optional, whether for livestock or pets
- Fresh EU approval for Portela for osteoarthritis in cats strengthens the growing companion animal therapy segment
- Solid key figures: 27.8% profit margin, expected EPS growth to USD 6.85 in 2026
Investment Thesis
Zoetis dominates the global animal health market with a unique combination of defensive qualities and innovative strength. The company is benefiting from two unstoppable trends: growing prosperity in emerging markets, which is leading to higher meat consumption and more professional livestock farming, and the increasing humanization of pets in developed markets. The latest EU approval for Portela, an innovative antibody therapy for cat pain, demonstrates the Group's pipeline strength. With an operating margin of over 40% and a robust business model that can withstand recessions, Zoetis offers German investors a rare combination of growth and defense.
Key risks and downside factors
Zoetis is the largest pure-play animal health company, operating across vaccines, pharmaceuticals, parasiticides and diagnostics for both companion animals and livestock. Its competitive landscape includes large diversified pharmaceutical groups with animal-health divisions such as Merck & Co., alongside pure-play competitors like Elanco, IDEXX, and Phibro. The company faces pressure from product pipeline maturation and patent expirations, competition in diagnostic and service platforms, and the pricing and scale advantages wielded by multinational rivals and large private players including Boehringer Ingelheim. Material risks center on product or regulatory setbacks, loss of market exclusivity, competitive pressure from both public and private peers, and potential disruptions to supply chains or manufacturing operations.
- Regulatory and approval risk represents a material constraint on revenue and pipeline value. Delays in the approval process, clinical trial failures, or adverse findings from regulatory bodies can each substantially reduce both near-term revenue and the longer-term worth of a company's development pipeline.
- Patent expirations and the entry of generic or alternative products—including combination offerings from competitors—create pressure on both margins and market share, eroding the protective moat that exclusivity once provided.
- Competitive platform risk: rivals with strong diagnostics, services, or integrated clinic and laboratory ecosystems—such as IDEXX, Mars/Antech, and emerging private innovators—could erode Zoetis's product stickiness and recurring revenue streams.
- Zoetis faces material exposure to supply chain disruptions through its dependence on global manufacturing networks, temperature-controlled logistics for biologics, and third-party suppliers. Production outages, quality recalls, and cost inflation represent substantive operational and financial risks stemming from this structural reliance.
Competitive landscape
Zoetis stands as the largest pure-play animal health company, operating across companion-animal and livestock segments with a portfolio spanning medicines, vaccines, parasiticides, and diagnostics. Its competitive landscape includes diversified pharmaceutical groups that maintain substantial animal-health divisions—notably Merck/MSD and Elanco—alongside specialist competitors in animal health and veterinary diagnostics such as IDEXX and Virbac. Private players including Boehringer Ingelheim and Ceva represent additional competitive pressure. The company faces material risks from its product pipeline and R&D execution, pricing pressures and generic competition from consolidated rivals, regulatory and safety compliance obligations, and cyclical exposure to livestock markets alongside vulnerability to zoonotic events and disease outbreaks.
| Company | Ticker |
|---|---|
| Merck & Co. Inc. | MRK.NYSE |
| Elanco Animal Health Incorporated | ELAN.NYSE |
| IDEXX Laboratories, Inc. | IDXX.NASDAQ |
| Dechra Pharmaceuticals PLC | DPH.LSE |
| Phibro Animal Health Corporation | PAHC.NASDAQ |
| Neogen Corporation | NEOG.NASDAQ |
Private competitors
- Boehringer Ingelheim (Animal Health)
- Ceva Santé Animale
- Norbrook Laboratories
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialCatalysts
- Q3 results on 4. November with expected sales of 2.41 billion USD
- Market launch of Portela in the EU following fresh approval for cat pain
- Further pipeline updates for monoclonal antibody therapies in the companion animal segment
- Expansion in emerging markets with growing demand for animal proteins
Analysis
Performance Figures of Zoetis Inc
Relative Performance vs Benchmarks
| Period | Zoetis Inc | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | -2.95% | -9.43% | -7.40% |
| 3M | -4.39% | -13.16% | -9.76% |
| 6M | -40.56% | -46.33% | -54.86% |
| 1Y | -51.20% | -59.74% | -73.19% |
| 3Y | -57.94% | -126.60% | -142.64% |
| 5Y | -62.22% | -128.28% | -149.29% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 11.8 | 3.2 | 9.8 | 10.7 |
| 1Y ago | 26.1 | 7.3 | 13.7 | 23.3 |
| 3Y ago | 39.7 | 10.7 | 19.0 | 43.9 |
| 5Y ago | 50.3 | 13.0 | 22.1 | 44.5 |
Frequently Asked Questions
Is Zoetis Inc a good investment?
What does Zoetis Inc do?
What are the key metrics for ZTS.NYSE?
How has Zoetis Inc's stock price performed?
How is ZTS.NYSE valued?
What are the growth catalysts for Zoetis Inc?
- Q3 results on 4. November with expected sales of 2.41 billion USD
- Market launch of Portela in the EU following fresh approval for cat pain
- Further pipeline updates for monoclonal antibody therapies in the companion animal segment
- Expansion in emerging markets with growing demand for animal proteins
What are the key risks when investing in ZTS.NYSE?
- Regulatory and approval risk represents a material constraint on revenue and pipeline value. Delays in the approval process, clinical trial failures, or adverse findings from regulatory bodies can each substantially reduce both near-term revenue and the longer-term worth of a company's development pipeline.
- Patent expirations and the entry of generic or alternative products—including combination offerings from competitors—create pressure on both margins and market share, eroding the protective moat that exclusivity once provided.
- Competitive platform risk: rivals with strong diagnostics, services, or integrated clinic and laboratory ecosystems—such as IDEXX, Mars/Antech, and emerging private innovators—could erode Zoetis's product stickiness and recurring revenue streams.
- Zoetis faces material exposure to supply chain disruptions through its dependence on global manufacturing networks, temperature-controlled logistics for biologics, and third-party suppliers. Production outages, quality recalls, and cost inflation represent substantive operational and financial risks stemming from this structural reliance.
Who are the main competitors of Zoetis Inc?
- Merck & Co. Inc. (MRK.NYSE)
- Elanco Animal Health Incorporated (ELAN.NYSE)
- IDEXX Laboratories, Inc. (IDXX.NASDAQ)
- Dechra Pharmaceuticals PLC (DPH.LSE)
- Phibro Animal Health Corporation (PAHC.NASDAQ)
- Neogen Corporation (NEOG.NASDAQ)
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 0.53 USD | 0.69% | 0.32% |
| 2026 | 0.53 USD | 0.43% | |
| 2026 | 0.53 USD | 0.43% | |
| 2025 | 0.50 USD | 0.35% | |
| 2025 | 0.50 USD | 0.33% | |
| 2025 | 0.50 USD | 0.34% | |
| 2025 | 0.50 USD | 0.30% | |
| 2024 | 0.43 USD | 0.24% | |
| 2024 | 0.43 USD | 0.24% | |
| 2024 | 0.43 USD | 0.28% | |
| 2024 | 0.43 USD | 0.23% | |
| 2023 | 0.38 USD | 0.24% | |
| 2023 | 0.38 USD | 0.22% | |
| 2023 | 0.38 USD | 0.21% | |
| 2023 | 0.38 USD | 0.23% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 9.47B | 9.26B | 8.54B | 8.08B | 7.78B |
| Operating income (EBIT) | 3.60B | 3.39B | 3.07B | 2.93B | 2.80B |
| Net income | 2.67B | 2.49B | 2.34B | 2.11B | 2.04B |
| Free cash flow | 2.28B | 2.30B | 1.62B | 1.33B | 1.74B |
| Total assets | 15.47B | 14.24B | 14.29B | 14.93B | 13.90B |
| Equity | 3.33B | 4.77B | 5.00B | 4.41B | 4.54B |
| Net debt | 7.18B | 4.76B | 4.72B | 4.51B | 3.26B |
PWP Leeway UG (haftungsbeschränkt)
